Browse the evidence

GLP-1 RAs show therapeutic potential in neurological disorders, including Alzheimer's and Parkinson's disease, by reducing amyloid-β/tau pathology, neuroinflammation, and promoting neuronal survival.

GLP-1 medications are being studied for Alzheimer's and Parkinson's disease. Some trials show promise in slowing brain volume loss, but results are mixed. They are not yet a standard treatment for these conditions. Consult a neurologist if interested in clinical trials.

Chronic consumption of monosodium glutamate (MSG) is associated with increased risk of obesity and weight gain, primarily through mechanisms involving hypothalamic damage, leptin resistance, and altered gut microbiota.

While MSG is legally safe, emerging research suggests high chronic intake, especially from processed foods with hidden MSG, may disrupt appetite regulation and contribute to weight gain. To mitigate potential risk, prioritize whole foods and check labels for hidden sources like hydrolyzed protein or yeast extract.

Specific additives found in UPFs, such as carrageenan and endocrine-disrupting chemicals like Bisphenol-A (BPA) and acrylamide, contribute to T2DM risk through mechanisms involving insulin resistance, inflammation, and gut microbiota alteration.

Be aware that certain additives (carrageenan, specific emulsifiers) and packaging-derived chemicals (BPA, phthalates) in UPFs may promote insulin resistance and inflammation. Reducing intake of products containing these specific ingredients, especially sugary beverages and processed meats, may lower T2DM risk.

Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.

If you have moderate OSA and are not sleepy (only snoring), ask your doctor if you can try tirzepatide alone. Since CPAP's benefit in asymptomatic moderate OSA is unclear, tirzepatide might resolve your OPA without the need for a machine. This requires monitoring and may not be suitable for everyone.

GLP-1 receptor agonists may have disease-modifying effects on osteoarthritis and osteoporosis by reducing inflammation and promoting bone formation.

If you have joint pain or weak bones, ask your doctor if your GLP-1 medication might offer extra protection. While weight loss is the main benefit, these drugs may also reduce inflammation in joints and help maintain bone density.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of hepatic decompensation events in patients with type 2 diabetes and compensated cirrhosis compared to DPP4 inhibitors and sulfonylureas.

If you have type 2 diabetes and compensated cirrhosis, GLP-1 receptor agonists may help reduce your risk of serious liver complications like fluid buildup or bleeding compared to other common diabetes medications. Discuss the benefits and risks with your doctor.

GLP-1 receptor agonists (GLP-1 RAs) reduce alcohol consumption and craving in patients with Alcohol Use Disorder (AUD) by modulating the mesolimbic dopamine reward pathway.

If you have AUD, especially if you also have obesity or Type 2 Diabetes, GLP-1 medications (like Semaglutide) may help reduce your alcohol intake and cravings by affecting brain reward pathways. This is an emerging off-label use, so discuss it with your doctor, particularly if standard treatments have failed or caused side effects.

GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.

If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.

Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.

Tirzepatide not only lowers blood sugar and helps with weight loss but may also protect your heart and blood vessels by reducing inflammation and improving lipid levels. This is especially important if you have diabetes and heart disease.

Native gut-produced GLP-1 exerts central anorectic effects via a neuroendocrine signaling mechanism involving the portal vein and vagal afferent nerves, without entering the brain.

Your body naturally produces GLP-1 after eating, which signals fullness to your brain via the vagus nerve. This is a fast, efficient system that doesn't require the hormone to cross into the brain tissue, explaining why synthetic GLP-1 drugs mimic this natural process effectively.

Preclinical evidence indicates that GLP-1 RAs directly improve skeletal muscle quality by reducing intramuscular fat (myosteatosis), enhancing mitochondrial biogenesis, and suppressing inflammatory markers, independent of weight loss.

Animal studies suggest GLP-1 drugs may improve the 'quality' of your muscle cells by boosting mitochondria and reducing inflammation. While this doesn't mean you'll build bigger muscles without exercise, it may help your muscles function better and recover faster, especially if you have diabetes or obesity.

GLP-1 receptor agonists exert direct anabolic and protective effects on skeletal muscle tissue, including promoting myogenesis, enhancing mitochondrial function, and reducing inflammation, which may help preserve muscle quality despite lean mass loss.

The drug may actively help protect muscle quality at a cellular level, but this does not guarantee muscle mass preservation without active lifestyle interventions.

Cerebral CCK acts as a neurotransmitter involved in memory and anxiety regulation, with knockout mice showing memory loss and increased anxiety, while exogenous CCK administration can induce panic attacks.

CCK is not just a gut hormone; it works in the brain to regulate anxiety and memory. While high doses can induce panic, natural CCK signaling may help modulate these states. This highlights the gut-brain axis.

Obesity-related complications (ORCs) such as hypertension, diabetes, and dyslipidemia are the primary drivers for initiating pharmacological obesity treatment, often delaying preventative care until complications are present and uncontrolled.

If you have obesity, do not wait for complications like high blood pressure or diabetes to seek treatment. The current system often delays medication until these issues arise, but early intervention with Obesity Management Medications (OMMs) can help control these complications and improve quality of life. Discuss preventative treatment with your doctor, especially if you have a family history of these conditions.

Gold-standard T2DM medications (metformin, SGLT2 inhibitors, GLP-1 agonists) modulate the redox state of skeletal muscle, potentially restoring metabolic function and insulin sensitivity.

Standard diabetes medications like metformin and GLP-1 agonists do more than lower blood sugar; they also interact with the redox state of your muscles. This interaction may help restore insulin sensitivity, offering a benefit beyond simple glycemic control.

Semaglutide use is associated with oral adverse effects, specifically xerostomia (dry mouth) and hyposalivation, likely due to prolonged GLP-1 receptor activation disrupting salivary gland signaling.

If you are taking semaglutide and experience persistent dry mouth, do not assume it is solely due to dehydration. The drug's prolonged action on salivary glands can reduce saliva production directly. Consult your provider for preventive oral care strategies to manage this side effect.

Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.

If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.

Gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, are frequent side effects of tirzepatide, particularly during initiation and titration phases.

GI side effects like nausea and diarrhea are common with tirzepatide, especially when starting or increasing the dose. Talk to your doctor about managing these symptoms with diet changes or medication to help you stay on treatment.

Targeting endogenous enteroendocrine cell (EEC) secretion to mimic postprandial hypersecretion of GLP-1 and other GI hormones offers a potential treatment for obesity and type 2 diabetes that avoids the side effects of exogenous GLP-1-based drugs.

Current research suggests that stimulating your gut to release its own GLP-1 (perhaps through specific nutrients or future drugs) might help with weight loss and blood sugar control without the nausea or nutrient malabsorption seen with current GLP-1 injections. This is still experimental.

Semaglutide induces adipose tissue remodeling in Type 2 Diabetes by promoting mitochondrial biogenesis, inducing beige adipocyte programming, and reducing visceral adiposity, leading to improved systemic insulin sensitivity and reduced ectopic fat deposition.

For individuals with T2DM or obesity, semaglutide offers benefits that go beyond simple weight loss. It actively remodels fat tissue, particularly visceral fat, making it more metabolically active and less inflammatory. This leads to improved insulin sensitivity and reduced liver fat, which are critical for long-term metabolic health. The medication is taken once weekly, with doses tailored to whether the goal is managing diabetes (up to 1.0 mg) or weight loss (up to 2.4 mg).

Tirzepatide promotes sustained improvements in skeletal muscle mitochondrial respiration and ATP production under lipotoxic conditions, whereas semaglutide and cagrilintide cause transient suppression that resolves over time.

If you are using incretin-based therapies like tirzepatide, this in vitro evidence suggests your muscle cells may become more efficient at producing energy over time, even under metabolic stress. While other drugs in this class (semaglutide, cagrilintide) show temporary dips in mitochondrial function, tirzepatide appears to enhance it. This supports the importance of resistance training to leverage these cellular adaptations for maintaining muscle quality.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.

If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.

Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.

While postmarketing reports of neoplasms are higher for GLP-1 RAs, they are still rare. The benefits of weight loss and mortality reduction likely outweigh this small risk for most patients.

Semaglutide is associated with a higher incidence of symptomatic gastrointestinal adverse events compared to dulaglutide in the context of emergency exposures.

If you experience severe nausea or vomiting on semaglutide, talk to your doctor. They might switch you to a different GLP-1 medication, like dulaglutide, which may have fewer gastrointestinal side effects for you.